01—Abstract
Summary
Summary of the 10-K filed March 27, 2002. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. reported significant revenue growth for the fiscal year ended December 31, 2001, reaching $233.8 milliona.
This growth was primarily driven by its antifungal drug, AmBisome, which accounted for 78% of total revenues, generating $181.6 millionb. The company also saw initial sales from Viread, its HIV treatment, which was approved in the U.S. in October 2001 and the EU in February 2002. A key strategic move was the sale of its oncology assets to OSI Pharmaceuticals in December 2001 for up to $200 million, allowing Gilead to sharpen its focus on infectious diseases.
Financially, Gilead remains in an investment phase, reporting a net loss for the year due to substantial research and development expenses, which totaled $185.6 millionc. The company ended the year with a strong cash position of $582.9 million, indicating healthy liquidity to fund ongoing development and potential future acquisitions. Investors should note the company's reliance on AmBisome and the critical role Viread is expected to play in future revenue generation and its competitive landscape.
02—Key points
Key Highlights
- Total revenues grew to $233.8 million in 2001, up from $195.6 million in 2000.
- AmBisome remains the primary revenue driver, contributing $181.6 million (78% of total revenue) in 2001.
- Viread, a new HIV treatment, achieved initial sales of $15.6 million in 2001 following its U.S. approval in October.
- Gilead sold its oncology assets to OSI Pharmaceuticals for up to $200 million, a strategic move to focus on infectious diseases.
- Research and Development (R&D) expenses increased to $185.6 million in 2001, reflecting continued investment in pipeline development.
- The company ended 2001 with $582.9 million in cash, cash equivalents, and marketable securities, demonstrating strong liquidity.
- Gilead reported a net income of $52.3 million in 2001, a significant turnaround from a net loss of $56.8 million in 2000, largely due to the oncology asset sale gain.
03—Questions
Frequently Asked Questions
What was Gilead's financial performance in 2001?
In 2001, Gilead reported total revenues of $233.8 million and a net income of $52.3 million. This net income was significantly boosted by a $157.8 million pre-tax gain from the sale of its oncology assets. The company's core operations continued to see revenue growth driven by AmBisome and initial sales from Viread, although R&D expenses remained substantial.
How significant are AmBisome and Viread to Gilead's revenue?
AmBisome was Gilead's leading revenue generator in 2001, contributing $181.6 million, or 78% of total revenues. Viread, approved late in 2001, generated $15.6 million in initial sales, representing 8% of total product sales. Gilead expects Viread sales to increase significantly in 2002.
What was the strategic rationale behind selling the oncology assets?
Gilead sold its oncology assets and operations to OSI Pharmaceuticals in December 2001 for up to $200 million. This strategic divestiture allowed Gilead to focus its resources and strengthen its core expertise in infectious diseases, including antivirals, antifungals, and antibacterials.
What is Gilead's R&D spending and its outlook?
Gilead invested heavily in R&D, with expenses totaling $185.6 million in 2001. This investment reflects the company's commitment to developing new treatments for life-threatening infectious diseases. For 2002, R&D expenses were expected to decrease by 15% to 25% compared to 2001 levels, partly due to the sale of oncology assets.
04—Continue